Elastography Imaging - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Elastography Imaging Market Analysis

The elastography imaging market is valued at USD 4.77 billion in 2025 and is forecast to reach USD 6.50 billion by 2030, expanding at a 6.38% CAGR. Growing clinical validation for non-alcoholic steatohepatitis (NASH) staging, rising cardiovascular and oncological use-cases, and strong demand for point-of-care ultrasound platforms are shaping growth trajectories. Artificial-intelligence-enabled automation shortens exam times by as much as 75%, easing the operator-dependency barrier in primary-care settings. Commercially viable handheld shear-wave probes priced below USD 4,000 are widening access in resource-limited facilities, especially across Asia-Pacific. M&A activity focused on clinical AI—such as GE HealthCare’s purchase of Intelligent Ultrasound—signals a pivot from hardware to software-led differentiation. Unfavorable reimbursement policies for elastography CPT codes and supply-chain shortages of high-frequency piezo crystals remain near-term restraints.

Global Elastography Imaging Market Trends and Insights

Rising incidence of chronic diseases & breast cancer

Escalating metabolic-dysfunction-associated steatotic liver disease prevalence drives routine liver stiffness measurement adoption, where two-dimensional shear-wave elastography achieves 94% accuracy at a 14.4 kPa cutoff . Combining ultrasound-guided attenuation parameters with shear-wave data stratifies MASLD patients by life-threatening event risk. Breast elastography now supports dense-breast screening, distinguishing malignant microcalcifications with 88% sensitivity and 86.7% specificity at a 62 kPa threshold. Growing oncology adoption bolsters equipment utilization in radiology suites. The dual-organ demand profile solidifies elastography as a preferred non-invasive alternative to biopsy.

Shift toward minimally invasive surgeries

Shear-wave elastography predicts rotator-cuff tendon quality before repair, enabling surgeons to tailor operative strategy more accurately. Robotic systems incorporate 3-D ARFI imaging to guide prostate procedures with agreement levels comparable to multiparametric MRI. AI-enhanced elastography automatically pinpoints biopsy targets, lowering sampling errors and procedure times. Strategic acquisitions, such as Hologic’s USD 350 million Sonata buy-out, highlight the commercial appeal of ultrasound-guided, fibroid-specific minimally invasive platforms. The technology’s intraoperative role is widening from liver to musculoskeletal and gynecological interventions.

Unfavorable reimbursement frameworks

Medicare restricts CPT 76981/76982 coverage to advanced hepatic fibrosis in defined chronic liver diseases, limiting broader screening uses. Aetna deems elastography investigational outside liver applications, stalling cardiology and musculoskeletal reimbursement. Prior-authorization hurdles lengthen administrative cycles and discourage routine ordering. The absence of standardized payment for cardiac elastography delays guideline endorsements. Evidence-based coverage expansions are expected only after large-scale outcome studies demonstrate cost savings.

Other drivers and restraints analyzed in the detailed report include:

1. Adoption of elastography for NASH-related fibrosis staging
2. AI-enabled point-of-care ultrasound elastography
3. High capital cost of MRI-based systems

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Ultrasound elastography captured 62.75% revenue in 2024, reflecting superior workflow integration and lower cost relative to MR platforms. That share equates to USD 2.83 billion of the elastography imaging market size in 2024. MR elastography advances at a 7.35% CAGR, underpinned by gold-standard accuracy for fibrosis staging, but uptake is limited to tertiary centers due to high acquisition costs. Continuous R&D delivers conformable ultrasound electronics for non-planar monitoring, while AI automation enhances repeatability across operator skill levels.

MR elastography’s precision sustains demand in complex hepatology practices, yet capital barriers spur hybrid purchasing strategies where ultrasound handles routine follow-up and MR is reserved for equivocal cases. Equipment vendors integrate AI reconstruction to shorten MR scan times and reduce per-exam cost. The balancing act between clinical gold-standard status and economic realities shapes long-term modality mix.

Shear-wave techniques represented 45.71% of 2024 sales, underlining their quantitative advantage and lower operator bias. Strain elastography’s 7.81% CAGR owes to software upgrades that convert existing scanners at minimal cost—a value proposition compelling in community hospitals. The elastography imaging market share leadership of shear-wave is reinforced by guideline endorsements for liver fibrosis and thyroid nodule assessment.

Transient elastography holds a niche in NASH monitoring, whereas ARFI benefits interventional radiology by providing real-time stiffness cues during needle placement. Hybrid solutions that fuse shear-wave with ARFI emerge to satisfy oncology procedural guidance. Diagnostic performance gains from machine-learning-based stiffness estimation continue to blur boundaries among technology types.

The Elastography Imaging Market Report is Segmented by Modality (Ultrasound Elastography, and More), Technology Type (Strain Elastography, and More), Imaging Technique (2-D Imaging, 3-D/4-D Imaging), Portability (Trolley-Based Systems, Portable Systems), Application (Radiology, and More), End-User (Hospitals, and More), and Geography. The Market Forecasts are Provided in Terms of Value (USD).

Geography Analysis

North America dominated revenue with a 41.25% share in 2024. Favorable reimbursement for liver elastography and rapid AI software clearance create a receptive regulatory environment. The United States initiated multi-center trials measuring elastography endpoints in NASH drug development, anchoring demand among hepatologists.

Europe maintains stable adoption as national health systems emphasize cost-effectiveness; portable devices offer lower total cost of ownership for district hospitals. The region’s imaging societies publish harmonized protocols, improving cross-country comparability and vendor neutrality.

Asia-Pacific delivers an 8.52% CAGR, fueled by expanding healthcare spending, large diabetic populations, and domestic manufacturing of affordable ultrasound chips. China’s NMPA issued updated Class III imaging guidelines in 2024, expediting domestic product registrations and spurring local competition. India’s point-of-care programs incorporate handheld elastography to screen fatty-liver disease in primary care.

The Middle East and Africa witness incremental adoption through private hospital groups investing in premium diagnostic services. South America shows steady growth as public health campaigns emphasize non-invasive cirrhosis detection, particularly in Brazil and Argentina.

List of Companies Covered in this Report:

1. Canon
2. Esaote
3. FUJIFILM
4. GE Healthcare
5. Supersonic Imagine
6. Hologic
7. Koninklijke Philips
8. Mindray
9. Resoundant Inc.
10. Samsung Medison Co. Ltd.
11. Siemens Healthineers
12. Hitachi
13. Butterfly Network Inc.
14. Clarius Mobile Health Corp.
15. Echosens SA
16. BK Medical ApS
17. Terason Corporation
18. Verasonics Inc.
19. Shenzhen Wisonic Medical Tech.
20. Alpinion Medical Systems
21. Ultrasonix Medical Corp.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support